Virpax Begins IND Enabling Studies of Envelta(TM) | Virpax Pharmaceuticals

Virpax Begins IND Enabling Studies of Envelta(TM)

admin2021-03-25T17:23:48-04:00March 25th, 2021|Press Release|

Nasdaq_Logo_wht

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

Nasdaq_Logo_wht

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

© Virpax^® Pharmaceuticals. All Rights Reserved.

© Virpax^® Pharmaceuticals. All Rights Reserved.

Follow @VirpaxPharma

Follow @VirpaxPharma